Abstract
Glaucoma is one of the leading causes of irreversible blindness worldwide. Currently, intraocular pressure is the only modifiable risk factor for glaucoma and therapies aimed at reducing the intraocular pressure are the only known methods to reduce the progression of optic neuropathy. Prostaglandin analogs, including travoprost, have been shown to be the most effective drug class in reducing intraocular pressure. This article will highlight the role of travoprost in the management of glaucoma with regards to its efficacy and side effects, and in relation to those of alternative prostaglandins.